Comparison of effects of dalteparin and enoxaparin on hemostatic parameters and von Willebrand factor in patients with unstable angina pectoris or non--ST- segment elevation acute myocardial infarction.

[1]  W. Klein,et al.  Limitation of vWf meta-analysis in LMWH comparison. , 2001, Journal of the American College of Cardiology.

[2]  E. Vicaut,et al.  Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. , 2000, Journal of the American College of Cardiology.

[3]  G. Montalescot,et al.  A rise of troponin and/or von Willebrand factor over the first 48 h is associated with a poorer 1-year outcome in unstable angina patients. , 2000, International journal of cardiology.

[4]  E. Antman,et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.

[5]  K. Huber,et al.  Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[6]  A. Siegbahn,et al.  Low-molecular Weight Heparin Reduces the Generation and Activity of Thrombin in Unstable Coronary Artery Disease , 1998, Thrombosis and Haemostasis.

[7]  R. Califf,et al.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .

[8]  H. Wendel,et al.  Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. , 1995, Circulation.

[9]  A. Frydman,et al.  Comparison of the Pharmacokinetic Profiles of Three Low Molecular Mass Heparins – Dalteparin, Enoxaparin and Nadroparin – Administered Subcutaneously in Healthy Volunteers (Doses for Prevention of Thromboembolism) , 1995, Thrombosis and Haemostasis.

[10]  P. Hufnagl,et al.  Hyperthermia stimulates plasminogen activator inhibitor type 1 expression in human umbilical vein endothelial cells in vitro. , 1991, The American journal of pathology.

[11]  M. Samama,et al.  The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg , 1988, Journal of clinical pharmacology.

[12]  G. Bratt,et al.  Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. , 1986, Thrombosis research.

[13]  B. Binder,et al.  Sandwich ELISA for t-PA antigen employing a monoclonal antibody. , 1986, Thrombosis research.